Kevin Horgan

Examiner
DISC Type : cs

Head of Research And Development at Melius MicroBiomics

Philadelphia, Pennsylvania, United States

Overview

Kevin Horgan is a physician-scientist and the Head of Research and Development at Melius MicroBiomics. He has extensive experience leading drug development across multiple therapeutic areas, with a distinct expertise in the microbiome, AI, and diagnostics. He studied Medicine and Physiology at University College Cork.

Outside of his direct professional roles, Kevin is an avid reader who enjoys the unique insights of columnists like Gillian Tett in the Financial Times. He follows developments at major pharmaceutical companies like Eli Lilly and academic institutions such as the University of Pennsylvania.

Unique fact: He led the clinical development of Emend, the first NK1 receptor antagonist approved for chemotherapy-induced nausea and vomiting.

Personality Overview

Late Adopter

Unexpressive

Overcautious

They do not like taking risks at all and go for proven options in the end.  They are heavily focused on quality and prefer doing things the right way, even if it takes time. The only way to convince them is by showing them examples and ample proof.

Topics They Care About

Microbiome Medicines
His company, Melius MicroBiomics, focuses on genetically engineering microbial medicine. He actively posts about the microbiome's potential to treat conditions like ulcerative colitis.
AI in Biomedicine
A core focus of his career is applying AI to transform biomedical research and enable precision medicine, holding advisory roles at AI-focused companies like Artificial Genius Inc.
Algorithmic Explanations
He is passionate about fulfilling Sydney Brenner's vision that explanations in biology will be algorithmic, a guiding principle in his work.

Media Appearances

Kevin has no verified media appearances

Work History

5-2025
Head of Research And Development at Melius MicroBiomics
12-2024
Senior Advisor, Biology and Medicine at Artificial Genius Inc.
10-2011
Medical Advisor at Liquid Biosciences - formerly Emerald Logic
4-2024 - 4-2025
Director at Alector
5-2023 - 3-2024
Co-Founder at Stealth Startup - Biotech

Education

1976 - 1984
Medicine & Physiology from University College Cork
Education details unavailable from Crescent College

More Information

Social Presence :

Prographics :

Exp : 14 Location : Philadelphia, Pennsylvania, United States Job Level : Mid-senior Designation : Head of Research And Development at Melius MicroBiomics
URL has been copied!

Insights For Selling To Kevin

During A Call Or A Meeting

DO's

  • Be firm in your communication and stay in control
  • Ask them which other stakeholders would be important for this purchase decision
  • Expect them to be vague in response to your questions, ask firmly and pointedly

DONT's

  • Don't rely on relationship building even if they act pleasantly
  • Avoid getting into storytelling mode, especially when they ask specific questions
  • Don't use phrases like 'do not worry', 'i promise' etc.

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Kevin is

  • For them, low risk and acceptance by others are very important, followed by proof of ROI.
  • Will you ever get a clear answer from Kevin

  • They are unlikely to say no, it's better to stop yourself once you have exhausted all the options.

Insights For Deal Planning

    How fast (or slow) will Kevin move?

  • They do not like to take decisions in a hurry, so they could be slow in making their mind up.
  • Can Kevin take some risk or not?

  • They are low on risk-appetite and prefer to make informed decisions.

You And Kevin

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.